For colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon, e.g. colonoscopy, barium enema or colonic resection.
Gilead Sciences, Inc. announced that the FDA approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir...
Gilead Sciences, Inc. announced that it will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg...
Gilead Sciences, Inc. announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF). In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.
Gilead Sciences, Inc. announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir...
Final results from the FEM-PrEP HIV-prevention trial of Truvada (emtricitabine/tenofovir disoproxil fumarate), from Gilead Sciences, reinforce the key role of...
Merck Inc., announced that the FDA has placed clinical holds on the investigational new drug applications (INDs) for the oral and implant formulations of islatravir (MK-8591) for HIV-1 pre-exposure prophylaxis (PrEP); the injectable formulation of islatravir for HIV-1 treatment and prophylaxis; and the oral doravirine/islatravir (DOR/ISL) HIV-1 once-daily treatment.
The FDA Antiviral Drugs Advisory Committee voted to recommend the use of Truvada (emtricitabine/tenofovir disoproxil fumarate) from Gilead Sciences ,as...
Gilead Sciences, Inc. announced important findings from the DISCOVER trial evaluating Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg...